Skip to contentC
Cannabis Bioscience International Holdings, Inc.
C
CBIHCannabis Bioscience International Holdings, Inc. Q1 2026 · 10-Q
Revenue$24.20K$24.20K−86.5% vs Q1 2025 Net Income-$82.65K-$82.65KN/M vs Q1 2025 EPS Diluted-$0.00-$0.00N/M vs Q1 2025 Gross Profit$16,057−90.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cannabis Bioscience International Holdings, Inc. · CIK 1411057 · Engraved from SEC EDGAR
Operating Cash Flow-$103,712N/M Margins · derivedGross margin66.4%−29.0 pt vs Q1 2025
Operating margin-309.0%−254.5 pt vs Q1 2025
Net margin-341.5%−298.9 pt vs Q1 2025
ended Aug 31, 2025 · filed Oct 22, 2025 · 52 d after period end